Chester County News and Community Website
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced that the U.S. Food and Drug Administration (FDA) has accepted an updated protocol for the company’s pivotal Phase 3 Alzheimer’s (AD) …
FDA Accepts Revised Protocol for Annovis Bio’s Phase 3 Alzheimer’s Study Read More
PHILADELPHIA, PA — Interius BioTherapeutics has secured approval from Germany’s Paul Ehrlich Institute (PEI) to expand its pioneering INVISE Phase 1 clinical trial into Europe. This marks the first-ever clearance …
Interius BioTherapeutics Expands Groundbreaking Gene Therapy Trial to Europe Read More
PHILADELPHIA, PA — Vittoria Biotherapeutics, Inc. has announced the launch of its Phase 1 clinical trial for VIPER-101, a cutting-edge gene-edited cell therapy aimed at treating relapsed and refractory (r/r) T …
Vittoria Biotherapeutics Launches Trial for Innovative T Cell Lymphoma Therapy Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that the Data and Safety Monitoring Board (DSMB) has cleared the continuation of its Phase 1/2 OCU410 ArMaDa clinical trial. This trial is …
Ocugen’s Gene Therapy Trial for Dry AMD Advances Read More
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) recently showcased promising data on istaroxime, an investigational treatment for early cardiogenic shock, at the Cardiovascular Clinical Trials Conference in Washington, DC. The …
Windtree Therapeutics Highlights Istaroxime’s Promise for Cardiogenic Shock Read More
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced encouraging initial results from its ongoing open-label extension (OLE) study evaluating long-term daily injections of nomlabofusp for Friedreich’s ataxia …
Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment Read More
DOYLESTOWN, PA — Aprea Therapeutics (Nasdaq: APRE) has announced a key update in its ongoing Phase 1/2a ABOYA-119 clinical trial for ATRN-119, aimed at treating advanced solid tumors with DNA damage …
Aprea Therapeutics Updates ABOYA-119 Trial with Twice Daily Dosing Read More
WILMINGTON, DE — Prelude Therapeutics (Nasdaq: PRLD) presented encouraging interim results from its Phase 1 trial of PRT2527, an investigational CDK9 inhibitor, at the 66th American Society of Hematology Annual Meeting. …
Prelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527 Read More
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced new data from a retrospective trial showcasing the long-term benefits of its investigational therapy, INO-3107, for patients with Recurrent Respiratory Papillomatosis (RRP). …
INOVIO Reports Promising Long-Term Data for INO-3107 in Treating RRP Read More
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) has announced encouraging results from its Phase 3 investigational study of icotrokinra (JNJ-2113), a groundbreaking oral peptide designed to selectively block …
Johnson & Johnson Reports Promising Results for Psoriasis Treatment Study Read More